Clinical and Genetic Features of Maturity-onset Diabetes of the Young in Pediatric Patients: a 12-year Monocentric Experience

Stefano Passanisi (stepassanisi@unime.it)
Universita degli Studi di Messina
https://orcid.org/0000-0002-4369-7798

Giuseppina Salzano
University of Messina: Universita degli Studi di Messina

Bruno Bombaci
University of Messina: Universita degli Studi di Messina

Fortunato Lombardo
University of Messina: Universita degli Studi di Messina

Research

Keywords: C-peptide, diagnosis, genetic testing, glucokinase, MODY, sulfonylureas

DOI: https://doi.org/10.21203/rs.3.rs-630278/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background.** A retrospective observational study was conducted to assess the prevalence of maturity onset diabetes of the young (MODY) in a large paediatric population of Southern Italy. Clinical and genetic features of the identified MODY patients were also described.

**Methods.** Genetic testing was performed in children and adolescents newly diagnosed with diabetes who presented autoantibody negativity and fasting C-peptide levels $\geq 0.8$ ng/mL. Patients with a low insulin daily dose and optimal glycaemic control after two years from diabetes onset were also investigated for monogenic diabetes, regardless of their autoimmunity status and/or C-peptide levels.

**Results.** A prevalence of 6.5% of MODY was found. In particular, glucokinase-MODY was the most common type of MODY. The mean age at diagnosis was 9.1 years. Clinical presentation and biochemical data were heterogeneous also among patients belonging to the same MODY group. No clear criteria to screen patients eligible for diagnostic investigations were identified.

**Conclusions.** Our findings highlight that a more detailed clinical evaluation of patients diagnosed with diabetes along with easier and less expensive approachability to genetic testing may allow diagnosing an increasing number of MODY cases. A correct, prompt diagnosis is crucial to choose the most appropriate treatment and offer adequate genetic counselling.

Introduction

Maturity onset diabetes of the young (MODY) is a rare condition characterized by autosomal dominant inheritance which is usually diagnosed before 25 years of age [1]. According to the latest clinical practice recommendations of the American Diabetes Association, MODY belongs to the monogenic diabetes syndromes [2]. It is frequently characterized by onset of hyperglycaemia caused by impairment of insulin secretion, with minimal or no defects in insulin action [3]. To date, at least 14 different genes have been reported to cause diabetes with a MODY-like phenotype [4]. Each MODY subtype is associated to different patterns (e.g. age of onset, clinical features, type of treatment) (Table 1) [5]. Although the traditional criteria for MODY include a family history of diabetes, sporadic *de novo* mutations in a number of causative genes have been reported [6-8].

MODY accounts for 1–5% of all cases of diabetes and 1–6% of paediatric diabetes cases [9-13]. Mutations in the hepatocyte nuclear factor 1-alpha (HNF1A), glucokinase (GCK), hepatocyte nuclear factor 4-alpha (HNF4A), and hepatocyte nuclear factor 1-beta (HNF1B) genes are the most frequently identified aetiologies of MODY. Other MODY genes include: PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8, and KCNJ11.

GCK-MODY, known as MODY 2, is the commonest subtype of monogenic diabetes in paediatric age, especially among Caucasian populations [11]. The GCK-MODY phenotype is characterized by mild fasting hyperglycaemia since birth, typically in the range of 5.5-8.0 mmol/l, which tends to remain stable.
or to increase only marginally with age [14]. The GCK mutational spectrum includes over 700 mutations distributed throughout the gene [15]. Patients with GCK-MODY do not usually require any pharmacological treatment [4]. HNF1A-MODY, also known as MODY-3, is more frequent in the United Kingdom and the Netherlands [16, 17]. Hyperglycaemia is the result of progressive beta-cell function deterioration over time in the absence of clinical signs of insulin resistance. Rarely, this type of MODY becomes apparent with mild-to-moderate ketoacidosis. Glycosuria is often present and is related to a low renal threshold, typically < 10 mmol/l [18]. Thus far, more than 400 causative mutations have been reported, and they are mainly found in exon 2 and exon 4 of the gene [19, 20]. HNF4A-MODY, also called MODY 1, is caused by heterozygous mutations in the HNF4A gene, resulting in a progressive β-cellular dysfunction [21]. HNF4A-MODY differs from HNF1A-MODY due to absence of glycosuria, older age at diagnosis, presence of reduced levels of apolipoproteins (AII and CIII), lipoprotein A and triglycerides and, above all, presence of macrosomia (50-60% of cases) and transient neonatal hyperinsulinemic hypoglycemia responsive to treatment with diazoxide [14]. More than 100 HNF1A mutations have been described [22]. Patients with HNF4A-MODY and HNF1A-MODY are generally sensitive to low-dose sulfonylurea [5].

Aim of this study was to assess the prevalence of MODY among a large paediatric population of Southern Italy newly diagnosed with diabetes. Secondary outcome of the study was to describe the main clinical and genetic features of the identified MODY patients.

**Material And Methods**

A retrospective analysis was conducted to select all patients who were admitted at our Paediatric Centre of Diabetes between January 2009 and February 2021 with a new diagnosis of diabetes. The study was conducted in accordance with the Helsinki Declaration, good clinical practice and all applicable laws and regulations. The study protocol was approved by the (local) Ethics Committee of the Medical University of Messina. The diagnosis of diabetes was made according to the current criteria of the ISPAD Clinical Practice Consensus Guidelines: classic symptoms of diabetes or hyperglycaemic crisis, with plasma glucose concentration ≥ 11.1 mmol/L (200 mg/dL) or fasting plasma glucose ≥ 7.0 mmol/L (≥ 126 mg/dL) or two hour postload glucose ≥ 11.1 mmol/L (≥ 200 mg/dL) during an oral glucose tolerance test (OGTT) or glycated haemoglobin (HbA1c) > 6.5% (48 mmol/mol) [4]. Data analysed included patient demographic and clinical variables.

Diabetes-specific islet cell autoantibodies (ICA), glutamic acid decarboxylase 65 autoantibodies (GADA), tyrosine phosphatase-like insulinoma antigen 2 (IA2), insulin (IAA), and β-cell-specific zinc transporter 8 autoantibodies (ZnT8) were measured. The presence of ICA was determined by immunofluorescence assay, while GADA, IA2, IAA, and ZnT8 were evaluated with enzyme linked immunosorbent assay. The identification of predisposing human leukocyte antigen (HLA) alleles (i.e. HLA-DRB1, HLA-DQA1, and HLA-DQB1) was also performed in every patient. In cases with the suspicion of monogenic diabetes, genetic tests were performed. In accordance with previous studies [13], selection criteria for genetic investigations included diabetes autoantibody negativity and fasting C-peptide levels ≥ 0.8 ng/mL at
time of diagnosis. However, some patients with a low insulin daily dose and optimal glycaemic control after two years from diabetes onset were also investigated for monogenic diabetes, regardless of their autoimmunity and/or C-peptide levels.

**Genetic testing**

Genetic testing for MODY was performed in two different laboratories located in Reggio Calabria and San Giovanni Rotondo, Italy. Analysis of MODY-causing genes was performed using the “HaloPlex HS Target Enrichment System” for sample preparation, which was thereafter sequenced on NextSeq 500 through 2x150 bp paired-end sequencing. The generated sequencing data was mapped to the human genome reference hg19. Raw data obtained from the genetic investigations were evaluated according to American College of Medical Genetics and Genomics guidelines. Confirmation studies were performed for variants that were considered to be pathogenic, or likely pathogenic, using Sanger sequencing.

**Results**

During the study period, a total of 565 children and adolescents were newly diagnosed with diabetes. Of these, 37 (6.5%) were diagnosed as MODY. In particular, 2 patients had a diagnosis of HNF4A-MODY (5.4%), 30 were diagnosed as GCK-MODY (81%) and the remaining 5 were HNF1A-MODY (13.5%). Mean age at diagnosis of MODY was 9.1 years (ranging from 0 to 16 years). Genotypic and phenotypic features of MODY patients are summarized in Table 2 and Table 3.

**HFN4A-MODY**

Two siblings (a male and a female) had a diagnosis of HFN4A-MODY at the age of 16 and 12, respectively. Diagnostic investigations started after discovering an occasional hyperglycaemia in one of the two siblings. At that time, her HbA1c was 6.1% (43 mmol/mol) and an OGTT confirmed the diagnosis of diabetes (two-hour postload blood glucose 12.1 mmol/l). Levels of the diabetes-specific autoantibodies were all negative. HLA was not predisposing to type 1 diabetes (T1D). On the suspicion of monogenic diabetes, genetic testing was performed. Genetic analysis revealed a frameshift mutation (HNF4A c.364_365insG) in exon 3 of the HNF4A gene. Thus, genetic investigations were extended to her families, revealing the same mutation in her brother, who was asymptomatic. Both siblings had normal liver function without morpho-structural alterations. Treatment with gliclazide was started at low daily dose. Thus far, after a 5-year-follow-up, both patients have optimal glycaemic control – last year HbA1c value < 6% (42 mmol/mol) – thus, oral hypoglycaemic agent withdrawal has been tried.

**GCK-MODY**

A total of 30 children were identified as GCK-MODY during the study period. Of these, 13 were male. Mean BMI Z-score at start of follow-up was -0.2 ± 1.1. Genetic analysis leading to diagnosis of monogenic diabetes was performed at the age of 8.5 ± 4.5 years. Mean HbA1c at diagnosis was 6.5 ± 0.5% (48 ± 6 mmol/mol), while basal C-peptide level was 0.8 ± 0.5 ng/ml. Oral glucose tolerance tests of these
patients showed a fasting blood glucose of 6.26 ± 0.93 mmol/l with a postload blood glucose after 120 minutes of 9.22 ± 1.89 mmol/l. All patients were investigated for diabetes-specific autoantibodies and the presence of T1D predisposing HLA: 2 patients were positive for GADA and one of these also had ICA and IA2; 10 patients showed a predisposing HLA. Mean weight at birth of the components of this group was 2.95 ± 0.6 kg. Of note, one patient diagnosed with GCK-MODY at the age of 6 years was also affected by cystic fibrosis [23]. An infant with a known family history of GCK-MODY (mother and her elder brother were affected) received a prenatal diagnosis after amniocentesis was performed. Almost all these patients are treated with a balanced diet regimen and regular physical activities without any pharmacological treatment. Only one patient started subcutaneous insulin therapy due to a brittle glycaemic control after 6 years from diagnosis. Gene sequencing revealed a missense mutation in the majority of cases. Frameshift, nonsense and splice site mutations were also identified. Sites of mutation were in exons 5, 6 and 7 in more than half the cases.

**HFN1A-MODY**

Five patients with HFN1A gene mutation were found in our study population. Two of these are siblings. Age at time of diagnosis ranged from 2 to 17 years. Diabetes onset in a 10-year-old girl was characterized by the occurrence of polyuria, polydipsia, and headache. Her glycaemia was 21.4 mmol/l, HbA1c 10.7% (94 mmol/mol). Ketonemia and ketonuria were negative. No family history of diabetes was present. Genetic investigations revealed a *de novo* missense mutation in the exon 3 of HFN1A gene (HFN1A-c.709A>G) [8]. Other patterns of clinical presentation varied from hypoglycaemic episodes to hyperglycaemia. One out of 5 patients was obese at time of diagnosis (Z-score BMI 1.7). Overall, BMI Z-score ranged from -1.10 to 1.7. HbA1c determination at onset was heterogeneous: in addition to the patient previously described, 2 patients showed a level above the range - 7.5% (58 mmol/mol) and 7.6% (60 mmol/mol) - while the remaining 2 were in the normal range: 5.1% (32 mmol/mol) and 5.4% (36 mmol/mol). Mean fasting and two hour postload glucose levels were respectively 7.02 ± 0.98 mmol/l and 14.15 ± 4.83 mmol/l. Basal C-peptide was in the normal range except for one patient who showed a value of 0.30 ng/dl. None of the patients were positive for T1D-specific autoantibodies. One case presented T1D predisposing heterozygous allele HLA DR4. Two of our HFN1A-MODY patients (siblings) currently practice subcutaneous insulin therapy due to failure with sulfonylurea treatment, while another two are on therapy with gliclazide. The remaining one patient with a recent diagnosis of HFN1A-MODY is still on lifestyle treatment because of satisfactory glycaemic control. Gene sequencing detected a missense mutation of the HFN1A gene affecting exons 1, 3, 4 and 7 in every patient.

**Discussion**

Over the past two decades, improved knowledge and awareness of monogenic diabetes, along with the development of increasingly more accurate and worldwide available molecular diagnostic techniques, have led to an increased estimate of the prevalence of MODY. The identification of genetic diagnosis is extremely important when choosing the most proper treatment plan. It is well established that patients affected by GCK-MODY do not require any pharmacological treatment [15], while patients with HNF1A or
HNF4A-MODY have a good response to sulfonylureas in term of glycaemic control and prevention of micro- and macrovascular complications [24].

Our 12-year-long experience identified a prevalence of MODY of 6.5% among a population of children and adolescents newly diagnosed with diabetes. This finding is consistent with a previous Italian multicentre study, which found a prevalence of 5.5% [25]. Conversely, other studies on paediatric diabetic populations revealed lower rates of prevalence ranging from 0.65% to 2.5% [13, 26-30]. The gap between these prevalence rates may be explained by different selection criteria adopted for patients undergoing genetic tests for MODY. Several studies on paediatric diabetic populations have systematically used diabetes-specific autoantibody negativity in combination with other biochemical parameters (i.e. basal C-peptide value and urinary C-peptide creatinine ratio) as screening methods to identify eligible patients for genetic tests for MODY [13, 30]. In an observational U.S. multicentre study, only patients with absence of diabetes-specific autoimmunity and C-peptide levels within the normal range were genetically investigated, resulting in a prevalence of MODY of 1.2% among children and adolescents with diabetes [13]. Similarly, Shepherd et al. [30] screened 808 UK children with diabetes. Only patients who had negative T1D autoantibodies and normal urinary C-peptide creatinine ratio underwent genetic tests, resulting in 20 patients diagnosed with MODY out of 82 selected children. Conversely, Johnson et al. found a prevalence of 2.1% in 821 Australian paediatric patients with diabetes screened for MODY regardless of their clinical features [28].

In our centre, genetic investigations for MODY were performed in presence of a clinical suspicion of non-T1D, without any strict criteria. We can speculate that serum C-peptide value alone is too stringent as it is well-known to be correlated with patients’ age and BMI [31]. Basal serum C-peptide was low in many of our patients affected by MODY, especially in the GCK-MODY subgroup. Furthermore, we found that diabetes-specific autoantibodies were positive in 2 patients diagnosed with MODY. GADA were present in both patients. GADA, especially alone, have a low predictive value for T1D when compared to other autoantibodies [32]. Existing evidence has shown a comparable incidence of positivity to autoantibodies between patients with MODY and the general population, of approximately 1% [33]. Finally, we can affirm that if we had excluded patients from gene sequencing on the basis of these strict criteria, we would have missed 13 diagnoses.

Interestingly, we found a relatively high number of patients belonging to the MODY group who presented HLA haplotype predisposing to T1D. Data from other studies show that the presence of HLA alleles DR3 and DR4 is not rare among MODY patients, ranging from 20% to 35.1% [29, 34]. The presence of HLA alleles DR3 or DR4 has been previously investigated as a discriminating factor between T1D and MODY [35]. However, our findings suggest that HLA alone cannot be considered as a relevant parameter to suspect MODY.

Regarding the frequency among MODY forms, most of our MODY patients have GCK gene mutations, confirming previous evidence among Caucasian populations [25, 26, 28, 29]. Discordance with other studies showing a higher prevalence of HNF1A-MODY [12, 13, 27] could be related to differences between
national healthcare systems. The Italian health service provides universal coverage to residents and public healthcare is largely free of charge. GCK-MODY is characterized by mild clinical signs that could be overlooked resulting in failure to diagnose unless the patient accesses tertiary diabetes outpatient services. This could explain its higher prevalence in countries providing easier access to tertiary care, in comparison to countries with other forms of public health, such as insurance-based ones.

In our study, mean HbA1c at diagnosis in GCK-MODY patients was lower than in HNF1A-MODY, confirming the results of another study [36], in which the assessment of HbA1c in combination with fasting glucose was proposed in the differential diagnosis between these two subtypes in subjects with suspect monogenic diabetes. In particular, those authors suggested considering HNF1A-MODY as the first hypothesis in patients presenting with HbA1c > 7.3% (56 mmol/mol) and fasting glucose < 8.33 mmol/l. However, in our study GCK and HNF1A patients showed comparable levels of fasting glucose, and none of them had a level of fasting glucose > 8.33 mmol/l, except for the HNF1A patient who presented DKA at diabetes onset.

It may be thought that dysglycaemia in obese children indicates a case of type 2 diabetes (T2D). However, auxological parameters from the MODY group show a significant number of patients presenting with a condition of overweight or obesity. A study on a cohort of obese and overweight patients with a clinical diagnosis of T2D reported that 4.5% of them were actually affected by monogenic diabetes [37]. Our data confirm that BMI may not only be indicative of T2D but also MODY should be suspected if other anamnestic and clinical conditions coexist.

To date, there are few data [38, 39] on OGTT response in children and adolescents affected by MODY. As expected, we found that patients affected by HNF1A-MODY had a markedly higher response to OGTT in terms of two hours postload blood glucose compared to GCK-MODY patients. Indeed, defects of the GCK gene cause a higher glycaemic set point of insulin secretion resulting in mild fasting hyperglycaemia, in contrast to other subtypes which are characterized by impaired insulin secretion and high glycaemic response after meals and during OGTT [4].

The coexistence of GCK MODY and cystic fibrosis is very rare. To the best of our knowledge, only two other cases of children suffering from both cystic fibrosis and GCK-MODY have been reported in literature [40, 41]. It is well known that patients with cystic fibrosis have a gradual deterioration in their glucose tolerance status that begins in the first years of the disease leading to the onset of cystic fibrosis related diabetes (CFRD) [42]. This type of diabetes is characterized by clinical signs at the onset that are very similar to those of MODY. Our experience highlights the need to consider monogenic diabetes also in children and adolescents with cystic fibrosis. Recognition of non-CFRD forms of diabetes in these patients is crucial in planning the most suitable treatment and follow-up.

Conclusions

Our findings suggest that a detailed clinical evaluation (i.e. family history, phenotypic features, diabetes-specific autoantibodies response, and assessment of endogenous insulin secretion) could be more useful
than restricted criteria as a first approach to screen diabetic children who need genetic testing for MODY. Finally, we speculate that easier and less expensive approaches to genetic investigations will allow to diagnose an increasing number of cases in the near future. A correct, prompt diagnosis is essential to start the most appropriate treatment, to offer adequate genetic counselling, and also to facilitate the diagnosis of monogenic diabetes in asymptomatic family members.

**Declarations**

**Funding**

This paper was not funded.

**Conflicts of interest/Competing interests**

The authors declare that they have no conflict of interest.

**Availability of data and material**

All published data are available if necessary.

**Code availability (software application or custom code)**

Not applicable

**Additional declarations for articles in life science journals that report the results of studies involving humans and/or animals**

Not applicable

**Author contributions**

SP drafted and wrote the paper; BB collected data; GS contributed to the discussion; FL reviewed the paper and accepted the final version.

**Ethics approval**

The study protocol was approved by the (local) Ethics Committee of the Medical University of Messina. The study was conducted in accordance with the Declaration of Helsinki

**Consent to participate**

All participants and their parents or legal guardians provided written informed consent.

**Consent for publication**

All authors have reviewed the content of this manuscript and provided consent for publication.
Acknowledgements

Not applicable.

References

1. Anık A, Çatlı G, Abacı A, Böber E. Maturity-onset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab. 2015;28(3-4):251-263. https://doi.org/10.1515/jpem-2014-0384

2. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33. https://doi.org/10.2337/dc21-S002

3. Misra S, Owen KR. Genetics of Monogenic Diabetes: Present Clinical Challenges. Curr Diab Rep. 2018;18(12):141. Published 2018 Oct 30. https://doi.org/10.1007/s11892-018-1111-4

4. Hattersley AT, Greeley SAW, Polak M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2018;19 Suppl 27:47-63. https://doi.org/10.1111/pedi.12772

5. Urakami T. Maturity-onset diabetes of the young (MODY): current perspectives on diagnosis and treatment. Diabetes Metab Syndr Obes. 2019;12:1047-1056. Published 2019 Jul 8. https://doi.org/10.2147/DMSO.S179793

6. Stanik J, Dusatkova P, Cinek O, et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia. 2014;57(3):480-484. https://doi.org/10.1007/s00125-013-3119-2

7. Yorifuji T, Higuchi S, Kawakita R, Hosokawa Y, Aoyama T, Murakami A, Kawai Y, Hatake K, Nagasaka H, Tamagawa N. Genetic basis of early-onset, maturity-onset diabetes of the young-like diabetes in Japan and features of patients without mutations in the major MODY genes: Dominance of maternal inheritance. Pediatr Diabetes. 2018 Nov;19(7):1164-1172. https://doi.org/10.1111/pedi.12714.

8. Salzano G, Passanisi S, Mammı C, Priolo M, Pintomalli L, Caminiti L, Messina MF, Pajno GB, Lombardo F. Maturity Onset Diabetes of the Young is Not Necessarily Associated with Autosomal Inheritance: Case Description of a De Novo HFN1A Mutation. Diabetes Ther. 2019 Aug;10(4):1543-1548. https://doi.org/10.1007/s13300-019-0633-3.

9. Kim SH. Maturity-Onset Diabetes of the Young: What Do Clinicians Need to Know?. Diabetes Metab J. 2015;39(6):468-477. https://doi.org/10.4093/dmj.2015.39.6.468.

10. Pettitt DJ, Talton J, Dabelea D, et al. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for diabetes in youth study. Diabetes Care. 2014;37(2):402-408. https://doi.org/10.2337/dc13-1838.

11. Mozzillo E, Salzano G, Barbetti F, Maffeis C, Lombardo F, Franzese A, Delvecchio M, Marigliano M. Survey on etiological diagnosis of diabetes in 1244 Italian diabetic children and adolescents: impact of access to genetic testing. Diabetes Res Clin Pract. 2015 Mar;107(3):e15-8. https://doi.org/10.1016/j.diabres.2015.01.003.
12. Johansson BB, Irgens HU, Molnes J, et al. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry. Diabetologia. 2017;60(4):625-635. https://doi.org/10.1007/s00125-016-4167-1.

13. Pihoker C, Gilliam LK, Ellard S, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013;98(10):4055-4062. https://doi.org/10.1210/jc.2013-1279.

14. McDonald TJ, Ellard S. Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem. 2013;50(Pt 5):403-415. https://doi.org/10.1177/0004563213483458.

15. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanné-Chantelot C, Ellard S, Gloyn AL. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009 Nov;30(11):1512-26. https://doi.org/10.1002/humu.21110.

16. Kyithar MP, Bacon S, Pannu KK, Rizvi SR, Colclough K, Ellard S, Byrne MM. Identification of HNF1A-MODY and HNF4A-MODY in Irish families: phenotypic characteristics and therapeutic implications. Diabetes Metab. 2011 Dec;37(6):512-9. https://doi.org/10.1016/j.diabet.2011.04.002.

17. Losekoot M, Broekman AJ, Breuning MH, de Koning EJ, Romijn JA, Maassen JA. Moleculaire diagnostiek bij aanwijzingen voor 'maturity onset diabetes of the young'; resultaten bij 184 patiënten [Molecular diagnosis on indication of maturity onset diabetes of the young; results from 184 patients]. Ned Tijdschr Geneeskd. 2005 Jan 15;149(3):139-43.

18. Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, Hattersley AT. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care. 2005 Jul;28(7):1751-6. https://doi.org/10.2337/diacare.28.7.1751.

19. Yeung RO, Hannah-Shmouni F, Niederhoffer K, Walker MA. Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes. Rev Endocr Metab Disord. 2018;19(1):35-52. https://doi.org/10.1007/s11154-018-9446-3.

20. Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat. 2006;27(9):854-869. https://doi.org/10.1002/humu.20357.

21. Ellard S, Bellanné-Chantelot C, Hattersley AT; European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51(4):546-553. https://doi.org/10.1007/s00125-008-0942-y.

22. Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat. 2013;34(5):669-685. https://doi.org/10.1002/humu.22279.

23. Salzano G, Passanisi S, Lucanto MC, Costa S, Pajno GB, Lombardo F. GCK-MODY in a child with cystic fibrosis: the doubt of the treatment plan. J Pediatr Endocrinol Metab. 2020;33(10):1359-1362.
24. Bacon S, Kyithar MP, Rizvi SR, Donnelly E, McCarthy A, Burke M, Colclough K, Ellard S, Byrne MM. Successful maintenance on sulphonylurea therapy and low diabetes complication rates in a HNF1A-MODY cohort. Diabet Med. 2016 Jul;33(7):976-84. https://doi.org/10.1111/dme.12992.

25. Delvecchio M, Mozzillo E, Salzano G, et al. Monogenic Diabetes Accounts for 6.3% of Cases Referred to 15 Italian Pediatric Diabetes Centers During 2007 to 2012. J Clin Endocrinol Metab. 2017;102(6):1826-1834. https://doi.org/10.1210/jc.2016-2490.

26. Schober E, Rami B, Grabert M, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med. 2009;26(5):466-473. https://doi.org/10.1111/j.1464-5491.2009.02720.x.

27. Galler A, Stange T, Müller G, et al. Incidence of childhood diabetes in children aged less than 15 years and its clinical and metabolic characteristics at the time of diagnosis: data from the Childhood Diabetes Registry of Saxony, Germany. Horm Res Paediatr. 2010;74(4):285-291. https://doi.org/10.1159/000303141.

28. Johnson SR, Ellis JJ, Leo PJ, et al. Comprehensive genetic screening: The prevalence of maturity-onset diabetes of the young gene variants in a population-based childhood diabetes cohort. Pediatr Diabetes. 2019;20(1):57-64. https://doi.org/10.1111/pedi.12766.

29. Carlsson A, Shepherd M, Ellard S, et al. Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study. Diabetes Care. 2020;43(1):82-89. https://doi.org/10.2337/dc19-0747.

30. Shepherd M, Shields B, Hammersley S, et al. Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care. 2016;39(11):1879-1888. https://doi.org/10.2337/dc16-0645.

31. Sosenko JM, Geyer S, Skyler JS, et al. The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. Pediatr Diabetes. 2018;19(3):403-409. https://doi.org/10.1111/pedi.12609.

32. Vehik K, Bonifacio E, Lernmark Å, et al. Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study. Diabetes Care. 2020;43(9):2066-2073. https://doi.org/10.2337/dc20-0126.

33. McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, Williams A, Hattersley AT, Ellard S. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med. 2011 Sep;28(9):1028-33. https://doi.org/10.1111/j.1464-5491.2011.03287.x.

34. Urrutia I, Martínez R, López-Euba T, Velayos T, Martínez de LaPiscina I, Bilbao JR, Rica I, Cañón L; Spanish Group for the Study of MODY and Type 1 diabetes. Lower Frequency of HLA-DRB1 Type 1
Diabetes Risk Alleles in Pediatric Patients with MODY. PLoS One. 2017 Jan 4;12(1):e0169389. https://doi.org/10.1371/journal.pone.0169389.

35. Møller AM, Dalgaard LT, Pociot F, Nerup J, Hansen T, Pedersen O. Mutations in the hepatocyte nuclear factor-1alpha gene in Caucasian families originally classified as having Type I diabetes. Diabetologia. 1998;41(12):1528-1531. https://doi.org/10.1007/s001250051101.

36. Delvecchio M, Salzano G, Bonura C, et al. Can HbA1c combined with fasting plasma glucose help to assess priority for GCK-MODY vs HNF1A-MODY genetic testing?. Acta Diabetol. 2018;55(9):981-983. https://doi.org/10.1007/s00592-018-1179-y.

37. Kleinberger JW, Copeland KC, Gandica RG, et al. Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med. 2018;20(6):583-590. https://doi.org/10.1038/gim.2017.150.

38. Massa O, Meschi F, Cuesta-Munoz A, et al. High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI. Diabetologia. 2001;44(7):898-905. https://doi.org/10.1007/s001250100530.

39. Stride A, Vaxillaire M, Tuomi T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2002;45(3):427-435. https://doi.org/10.1007/s00125-001-0770-9.

40. Hangül M, Erdoğan M, Hatipoğlu N, Köse M. Maturity-onset diabetes of the young: Different diabetes in an infant with cystic fibrosis. Pediatr Pulmonol. 2020;55(5):E5-E7. https://doi.org/10.1002/ppul.24746.

41. Scully KJ, Sawicki G, Kremen J, Putman MS. Monogenic Diabetes in a Child with Cystic Fibrosis: A Case Report and Review of the Literature. J Endocr Soc. 2020;5(1):bvaa165. Published 2020 Nov 2. https://doi.org/10.1210/jendso/bvaa165.

42. Mozzillo E, Franceschi R, Piona C, et al. Diabetes and Prediabetes in Children With Cystic Fibrosis: A Systematic Review of the Literature and Recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED). Front Endocrinol (Lausanne). 2021. https://doi.org/10.3389/fendo.2021.673539.

Tables

Table 1. Etiological classification and main features of different types of MODY
| Gene    | Locus      | Hyperglycaemia | Organs affected         | Treatment       | Complications |
|---------|------------|----------------|-------------------------|-----------------|---------------|
| HNF-4α  | 20q        | Progressive    | Pancreas/liver          | Diet/insulin    | Frequent      |
| GCK     | 7p         | Mild           | Pancreas/liver          | Diet            | Rare          |
| HNF-1 α | 12q        | Mild/progressive | Pancreas/kidney/others | OHAs/insulin    | Frequent      |
| IPF1    | 13q        | Progressive    | Pancreas/others         | Insulin/diet    | Rare          |
| HNF-1β  | 17q        | Mild/progressive | Pancreas/kidney/others | Insulin         | Unknown       |
| NEUROD1 | 2q         | Mild           | Pancreas/others         | Diet/insulin    | Unknown       |
| KLF11   | 2p         | Mild           | Pancreas/others         | Diet            | Unknown       |
| CEL     | 2q         | Mild/progressive | Pancreas/others         | Pancreatic enzymes/insulin | Unknown       |
| PAX4    | 7q         | Mild           | Pancreas/others         | Diet            | Unknown       |
| INS     | 11p15.5    | Mild/progressive | Pancreas               | Diet/Insulin    | Unknown       |
| BLK     | 8p23       | Mild/progressive | Pancreas               | Diet/insulin    | Unknown       |
| ABCC8   | 11p15.1    | Mild/progressive | Pancreas               | OHAs/Insulin    | Unknown       |
| KCNJ11  | 11p15.1    | Mild/progressive | Pancreas               | OHAs/insulin    | Unknown       |

OHAs: oral hypoglycaemic agents

**Table 2.** Mutations and genotype of study MODY patients.
| N | Diagnosis       | Exon | Type of mutation   | Nucleotide change    | Protein effect   |
|---|----------------|------|--------------------|---------------------|-----------------|
| 1 | HFN4A MODY     | 3    | Frameshift         | c.364_365insG       | p.Ala123fs      |
| 2 | HFN4A MODY     | 3    | Frameshift         | c.364_365insG       | p.Ala123fs      |
| 3 | GCK MODY       | 10   | Frameshift         | c.440_450del        | p.His147fs      |
| 4 | GCK MODY       | 2    | Missense           | c.106C>T            | p.Arg36Trp      |
| 5 | GCK MODY       | 7    | Frameshift         | 41756insG           | Unknown         |
| 6 | GCK MODY       | 7    | Frameshift         | 41756insG           | Unknown         |
| 7 | GCK MODY       | 5    | Nonsense           | c.559C>T            | p.Arg187Trp     |
| 8 | GCK MODY       | 6    | Missense           | c.674G>A            | p.Arg225His     |
| 9 | GCK MODY       | 8    | Missense           | c.955G>A            | p.Gly318Arg     |
| 10| GCK MODY       | 8    | Missense           | c.955G>A            | p.Gly318Arg     |
| 11| GCK MODY       | 6    | Missense           | c.682G>C            | p.Thr228Ala     |
| 12| GCK MODY       | 6    | Missense           | c.682G>C            | p.Thr228Ala     |
| 13| GCK MODY       | 6    | Missense           | c.682G>C            | p.Thr228Ala     |
| 14| GCK MODY       | 7    | Missense           | c.781G>A            | p.Gly261Arg     |
| 15| GCK MODY       | 8    | Missense           | c.955G>A            | p.Gly318Arg     |
| 16| GCK MODY       | 5    | Nonsense           | c.3989-9G>A         | Unknown         |
| 17| GCK MODY       | 5    | Nonsense           | c.3989-9G>A         | Unknown         |
| 18| GCK MODY       | Intron 9 | Splice site | IVS9-2A>G | Unknown |
| 19| GCK MODY       | Intron 9 | Splice site | IVS9-2A>G | Unknown |
| 20| GCK MODY       | 5    | Missense           | c.538A>G            | p.Asn180Asp     |
| 21| GCK MODY       | 5    | Missense           | c.544G>A            | p.Val182Met     |
| 22| GCK MODY       | 5    | Frameshift         | Deletions of 21 nucleotides | Unknown |
| 23| GCK MODY       | 2    | Missense           | c.113A>C            | p.Gln38Pro      |
| 24| GCK MODY       | Intron 1 | Splice site | IVS1+1G>T | Unknown |
| 25| GCK MODY       | Intron 1 | Splice site | IVS1+1G>T | Unknown |
| 26| GCK MODY       | 9    | Frameshift         | Deletions of 21 nucleotides | Unknown |
| 27| GCK MODY       | 5    | Nonsense           | c.3989-9G>A         | Unknown         |
| 28| GCK MODY       | 7    | Missense           | c.784G>A            | p.Gly262Arg     |
|   | GCK MODY |   | Missense | c.1261A>G | p.Ser131Pro |
|---|---------|---|----------|----------|-------------|
| 29 | GCK MODY | 10 | Missense | c.796G>A | p.Glu265Lys |
| 30 | GCK MODY | 7  | Missense | c.796G>A | p.Glu265Lys |
| 31 | GCK MODY | 7  | Missense | c.116A>C | p.Gln38Pro |
| 32 | GCK MODY | 2  | Missense | c.229G>A | p.Asp77Asn |
| 33 | HFN1A MODY | 1 | Missense | c.229G>A | p.Asp77Asn |
| 34 | HFN1A MODY | 1 | Missense | c.1340C>T | p.Pro447Leu |
| 35 | HFN1A MODY | 7 | Missense | c.709A>G | p.Asn237Asp |
| 36 | HFN1A MODY | 4 | Missense | c.815G>A | p.Arg272His |

**Table 3.** Clinical characteristics of study GCK-MODY and HFN1A-MODY patients.
|                                | GCK-MODY     | HNF1A-MODY  |
|--------------------------------|--------------|-------------|
| **Number of patients**         | 30 (81%)     | 5 (13.5%)   |
| **Age at diagnosis (yrs)**     | 8.5 ± 4.5    | 9.9 ± 5.6   |
| **BMI at diagnosis (Z-score)** | -0.2 ± 1.1   | 0.6 ± 1.16  |
| **HbA1c at onset (%)**         | 6.5 ± 0.5    | 7.3 ± 2.2   |
| **HbA1c at onset (mmol/mol)**  | 48 ± 6       | 56 ± 24     |
| **OGTT: 0% glucose (mmol/l)**  | 6.26 ± 0.93  | 7.02 ± 0.98 |
| **OGTT: 120% glucose (mmol/l)**| 9.22 ± 1.89  | 14.15 ± 4.83|
| **C-peptide at onset (ng/dl)** | 0.8 ± 0.5    | 1.8 ± 1.0   |
| **Weight at birth (kg)**       | 2.95 ± 0.6   | 2.90 ± 0.5  |
| **HLA**                        |              |             |
| DR3 and/or DR4                 | 10 (33.3%)   | 1 (20%)     |
| **Autoantibodies**             |              |             |
| ICA                            | 1            | 0           |
| IA2                            | 1            | 0           |
| GADA                           | 2            | 0           |
| **Treatment**                  |              |             |
| Diet only                      | 29           | 1           |
| Insulin                        | 1            | 2           |
| OHA                            | 0            | 2           |